Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

Grem, Jean L., Morrison, Geraldine, Guo, Xiao-Du, Agnew, Elizabeth, Takimoto, Chris H., Thomas, Rebecca, Szabo, Eva, Grochow, Louise, Grollman, Frank, Hamilton, J. Michael, Neckers, Len, Wilson, Richard H. · 2005 · Journal of Clinical Oncology

Abstract

Purpose: To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks. Patients and Methods: Nineteen patients received 17-AAG over six dose levels (10 to 56 mg/m 2) using an accelerated titration scheme. Drug levels of 17-AAG were determined by high-performance liquid chromatography. Biologic effects of 17-AAG were monitored by changes in the content of target proteins by immunoblot analysis of lysates prepared from peripheral-blood mononuclear cells. Results: Toxicity was acceptable at doses up to 28 mg/m 2. The cohort was expanded to three patients at 40 mg/m 2 because a second occurrence of grade 2 hepatic transaminitis occurred. Two of six assessable patients who received 56 mg/m 2 had reversible, grade 3 hepatic transaminitis. Five additional patients were enrolled at 40 mg/m 2; none had dose-limiting toxicity. The maximum plasma concentrations (C max) of 17-AAG at 40 and 56 mg/m 2 were 1,724 and 2,046 ng/mL, respectively; the average plasma exposures (AUC) were 2,809 and 6,708 hours·ng/mL, respectively. Less than 3% of the daily dose was excreted into the urine. Clearance did not correlate with body-surface area. Possible biologic activity was suggested by apparent increased protein content of either glucose-related 78 kd protein or heat shock protein 70 with ≥ 14 mg/m 2 and decreased protein content of either Lck or Raf1 with ≥ 28 mg/m 2 of 17-AAG. Conclusion: 17-AAG 40 mg/m 2 (median dose, 70 mg) was well tolerated when given daily for 5 days every 3 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.12.085

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 242

Metadata

Authors
Grem, J. L., Morrison, G., Guo, X.-D., Agnew, E., Takimoto, C. H., Thomas, R., Szabo, E., Grochow, L., Grollman, F., Hamilton, J. M., Neckers, L., & Wilson, R. H.
Venue
Journal of Clinical Oncology
Published
2005-03-20
Volume
23
Issue
9
Pages
1885-1893
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2158341833
Cited by
242
References
1
FWCI
12.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.2005.12.085
The paper
Grem, J. L., Morrison, G., Guo, X.-D., Agnew, E., Takimoto, C. H., Thomas, R., Szabo, E., Grochow, L., Grollman, F., Hamilton, J. M., Neckers, L., & Wilson, R. H. (2005). Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.12.085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.